Biopharma · FDA Approvals · Stock
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and m…
Assets on file: CELMoD
Dated catalysts for EVO, including recently decided ones.
Nothing scheduled in this window.
Every first-hand event for EVO, newest first.
Evotec/BMS: Second CELMoD IND Accepted by FDA
The FDA has accepted the IND for the second molecular glue degrader (CELMoD) candidate discovered under the Evotec-BMS protein degradation partnership. This follows the first candidate entering Phase 1 in March 2026; the second is expected to enter Phase 1 in 2027.
Companies in the same sector closest to EVO in market value.